Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...

– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – PNH is a blood disorder characterized by complement-mediated ...

The FDA has approved eculizumab for the treatment of atypical hemolytic uremic syndrome (aHUS) in both children and adults, a potentially life-threatening condition. The drug, marketed by Alexion ...

The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and ...

The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 ...

LONDON, United Kingdom — For patients with atypical hemolytic uremic syndrome (HUS), the improvement in estimated glomerular filtration rate (eGFR) is significantly better when eculizumab (Soliris, ...

Hemolytic uremic syndrome (HUS) is a condition that affects the blood vessels in your kidneys. When the vessels are damaged, they form clots that block the kidney's regular filtering system, leading ...

The research population consisted of 65 aHUS patients, referred to the Paediatric Nephrology Centre of the Radboud University Medical Centre. The patients were of Dutch or Belgian origin with a ...